DSIP

What DSIP does

DSIP is a nine-amino-acid peptide studied mainly in small, older experiments. Early sleep reports were positive, but controlled insomnia studies found little clinical benefit. Online injection and nasal routines are not established sleep treatments. Low blood pressure occurred in an IV study, and product quality adds risk.

• In small early studies, people slept longer with fewer wake-ups, but later controlled insomnia studies found little benefit. (Studied in a trial)
• In an older study with no placebo group, withdrawal signs eased or went away in 97% of opioid and 87% of alcohol patients. (Studied in a trial)
• People report deeper sleep or fewer wake-ups at night, though others notice no benefit or even worse sleep. (Reported by users)
• In a tiny pilot with no placebo group, 6 of 7 people in pain had lower pain scores, and their low mood also improved. (Studied in a trial)

Uses in the sources

• Studied for chronic insomnia. Small early reports were positive; the 1987 and 1992 controlled studies found little clinical benefit. (Studied in a trial) (source)
• Studied for alcohol and opioid withdrawal in uncontrolled inpatient studies. Results do not establish a home withdrawal regimen. (Studied in a trial) (source)
• A narcolepsy case and a seven-person pain pilot reported improvement; neither establishes effectiveness. (Studied in a trial) (source)
• Nasal preparations were studied for retinal responses in diabetes. These reports did not test insomnia. (Studied in a trial) (source)
• People report bedtime injections, intermittent nasal use and cycles. Benefits range from better sleep to no effect or worse insomnia. (Reported by users) (source)

DSIP dosage

Typical reported dose: 500 mcg at bedtime

• Morning infusion: 25 nmol/kg: 25 nmol/kg IV over 20 minutes one infusion on the active crossover day, into a vein. Studied in a trial. Studied in: Six healthy adults, four men and two women. (source)
• Bedtime crossover: 25 nmol/kg: 25 nmol/kg IV over 4 minutes on active nights in P-D-P or D-P-D sequence, into a vein. Studied in a trial. Studied in: Six middle-aged adults with chronic insomnia. (source)
• Single evening infusion: 25 nmol/kg IV over 4 minutes single dose, into a vein. Studied in a trial. Studied in: Healthy volunteers and adults with insomnia in five small experiments. (source)
• Four evening infusions: 25 nmol/kg IV over 4 minutes on four evenings once daily for four consecutive evenings, into a vein. Studied in a trial. Studied in: Healthy volunteers and adults with insomnia in five small experiments. (source)
• Six morning infusions: 25 nmol/kg IV on six consecutive mornings once daily for six mornings, into a vein. Studied in a trial. Studied in: Healthy volunteers and adults with insomnia in five small experiments. (source)
• Seven nights: 30 nmol/kg: 30 nmol/kg IV each night on laboratory nights 3-9 once nightly for seven consecutive nights, into a vein. Studied in a trial. Studied in: 14 middle-aged adults with chronic insomnia. (source)

These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.

Work out syringe units with the dosing calculator

How to mix DSIP

Comes as: Freeze-dried powder vials reported by users, Homemade or premixed nasal sprays reported by users.

Mixed with: Community reports use bacteriostatic water for injections and sterile saline for nasal sprays. Neither is an approved DSIP sleep formulation..

Common vial sizes: 5, 10 mg. Common water amounts: 2, 3, 10 mL.

• Reported examples: 5 mg with 2 mL or 3 mL bacteriostatic water; 10 mg with 10 mL saline for a nasal preparation.
• These are community mixing amounts. They do not establish stability, a sterile process or a validated delivered nasal dose.
• Syringe units measure volume, not peptide mass. Spray output must be measured; it cannot be assumed from bottle volume.
• A trial’s IV diluent or dose does not validate home subcutaneous or nasal preparation.

Before mixing: No validated dry-vial storage schedule was found for the community products described.

After mixing: No verified DSIP-specific after-mixing shelf life was found. A clear solution does not establish sterility or potency.

DSIP side effects and risks

Reported side effects

• Transient sweating, headache, nausea or vertigo: 9/107 had one or more minor events in the IV withdrawal series; counts for each symptom were not given., mild. Stop and seek assessment if symptoms persist or worsen. (source)
• Low blood pressure: 2/107 in the IV withdrawal series; one worsened after another injection. Route specific community rates are unknown., serious. Fainting or severe dizziness needs urgent care. (source)
• Repeated discomfort with sweating and nausea: 1/107 in the IV withdrawal series; episodes lasted about 15 minutes and were classified as serious by FDA., serious. Stop and get medical assessment. (source)
• Faster heart rate: Observed during the 24 person anesthesia study; event counts and absolute change unavailable in the abstract., moderate. Report palpitations; chest pain or fainting needs urgent care. (source)
• Worse insomnia or next-day grogginess: Community reports; no reliable denominator or proven causal link., moderate. Stop if sleep or daytime alertness worsens; avoid driving while impaired. (source)
• Low mood or loss of motivation: One detailed user report at 100 mcg five nights weekly; no clinical incidence estimate., moderate. Stop and discuss mood changes with a clinician. (source)
• Allergic or immune reaction: FDA warns about potential immune reactions to peptide impurities or aggregates; DSIP incidence is unknown., serious. Breathing trouble, throat swelling or collapse needs emergency help. (source)

Stop and get help if

• Throat or tongue swelling, trouble breathing, or collapse: Stop exposure and call emergency services now.
• Fainting, severe dizziness or chest discomfort after dosing: Stop and get urgent medical assessment.
• Fever, spreading injection-site redness or feeling acutely unwell: Stop injections and get urgent assessment for infection or contamination.
• Very low blood sugar with confusion or inability to swallow: Use the prescribed emergency plan and call emergency services.

Who should avoid it

• pregnant: No adequate pregnancy or fetal-safety data. Avoid exposure during pregnancy.
• breastfeeding: Safety after taking DSIP while breastfeeding is unknown. Native DSIP-like material in milk does not establish drug safety.
• tryingToConceive: Reproductive safety has not been established. Avoid exposure while trying to conceive.
• under18: No established pediatric dose or adequate child-safety program. The reference uses an adult-only screen.
• other: A previous serious allergic reaction should stop re-exposure to that substance.
• other: Low blood pressure occurred with IV dosing, including worsening after repeat exposure.
• heartCondition: An anesthesia study found faster heart rate and altered heart-rate variability. Safety in heart disease is unknown.
• kidneyDisease: No validated dose adjustment or safety data for kidney disease. Elevated native DSIP signals during dialysis do not define drug clearance.
• liverDisease: Drug exposure, safety and dose adjustment in liver disease are unknown.
• psychiatricCondition: Users have reported low mood, low motivation or worse sleep. Controlled psychiatric safety data are lacking.
• sleepApnea: DSIP has not been shown to improve sleep apnea. Breathing pauses and daytime sleepiness need assessment.
• surgeryPlanned: Tell the anesthesia team about DSIP. One human trial found lighter anesthesia and faster heart rate.
• diabetes: A small uncontrolled combination-product study reported lower post-meal glucose. Its effect with diabetes medicines is unknown.
• testedAthlete: DSIP is not named on the 2026 list. S0 coverage depends on therapeutic approval status; obtain an anti-doping ruling.

Interactions

• Captopril and other ACE inhibitors: A review raises a theoretical peptidase interaction with captopril. Clinical effects and extension to other ACE inhibitors are untested.
• Anesthetic drugs: DSIP altered anesthesia depth and heart-rate signals with propofol and isoflurane. Other anesthetics were not established as safe combinations.
• Alcohol, opioids and sleep medicines: DSIP combination effects are poorly studied and may affect alertness unpredictably. It is not an established substitute for supervised withdrawal.
• Insulin and sulfonylureas: A small uncontrolled study reported lower post-meal glucose. A DSIP interaction is unproven; avoid self-adjusting diabetes medicines.

Product quality risks

• Health Canada’s DSIP-inclusive warning describes wrong amounts, unknown ingredients, microbes, endotoxins and particles in unauthorized peptides.
• FDA found inconsistent salt and identity descriptions in DSIP nomination documents and warned about peptide impurities and aggregates.
• No peer-reviewed survey quantifying purity or contamination of online DSIP vials was found. There is no reliable DSIP-specific failure rate.

What to expect

A six-person sleep study tested acute IV doses; it does not establish a multiweek injection cycle.

51 primary human research reports are listed, including biomarkers and overlapping series. Sleep trials are small and mixed; no human subcutaneous trial was found.

Key studies

• Healthy volunteers: morning infusion: Median sleep time during the next 130 minutes was 59% greater with DSIP than placebo. (source)
• Early insomnia letter: No arm-level results were available in the retrieved record. (source)
• Six adults with insomnia: Longer, less interrupted sleep was reported; benefit began in hour 2 and lasted up to 6 hours. (source)
• Five early human experiments: Four evening doses reportedly normalized disturbed sleep; daytime tests suggested greater alertness. (source)
• Insomnia after brain-stem injury: Baseline sleep was under 4 hours; DSIP improved sleep reversibly, without normalizing REM latency. (source)
• Alcohol and opioid withdrawal pilot: 49 were evaluable; 48 improved: 22 alcohol patients and 26 of 27 opioid patients. (source)

DSIP FAQ

• Is DSIP FDA-approved? No FDA-approved product or dose. Category 2 removal was not approval. An advisory vote does not change compounding law.
• How do people take it? Under the skin, once nightly. One poster described a four-week cycle. Source: reported by users, not an established dose.
• What's the difference between DSIP and CJC-1295 without DAC? DSIP: an experimental sleep peptide with small, mixed human studies and no FDA-approved dose. CJC-1295 without DAC: a peptide intended to trigger growth hormone release, with no human dosing study found. Why people pair them: users add DSIP hoping to improve deep sleep alongside a growth-hormone-release regimen.
• Can I take it with CJC-1295 without DAC? Users add DSIP hoping to improve deep sleep alongside a growth-hormone-release regimen. No human trial of this sleep stack was found. Heart-rate, glucose and fluid-related risks cannot be inferred from a sleep tracker. Source: reported by users. Ask a doctor before combining anything.
• Is it banned in sport? It is unclear (WADA 2026). S0 prohibits drugs without approval by any government health authority. Relevant foreign approval status was not resolved; ask the anti-doping authority.
• How long does a mixed vial last? No verified DSIP-specific after-mixing shelf life was found. A clear solution does not establish sterility or potency.